ESR1 and invasive breast carcinoma: In the current study with 2173 invasive breast cancer patients, we demonstrated a high concordance rate for ER, PR, and HER2 status, but a fair agreement for Ki67 and molecular subtype evaluation between CNB and OEB samples.